{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:25:14Z","timestamp":1792207514482,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":704,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1002\/rth2.12457","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T10:08:32Z","timestamp":1607422112000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND\/UCLA modified Delphi panel method"],"prefix":"10.1016","volume":"5","author":[{"given":"Adam","family":"Cuker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Despotovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Liebman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Wasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beenhouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-642X","authenticated-orcid":false,"given":"Sarah N.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1002\/rth2.12457_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: a population\u2010based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1002\/rth2.12457_bb0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2009","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1002\/rth2.12457_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1002\/rth2.12457_bb0025","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"9664","key":"10.1002\/rth2.12457_bb0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"9763","key":"10.1002\/rth2.12457_bb0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6\u2010month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/rth2.12457_bb0040","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists: sustained ITP remissions after TPO receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion (Paris)"},{"issue":"6","key":"10.1002\/rth2.12457_bb0045","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12888","article-title":"The temporary use of thrombopoietin\u2010receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study","volume":"165","author":"Mah\u00e9vas","year":"2014","journal-title":"Br J Haematol"},{"issue":"04","key":"10.1002\/rth2.12457_bb0050","first-page":"1","article-title":"Sustained responses following treatment with romiplostim in immune thrombocytopenia: a single\u2010centre experience","volume":"02","author":"Provan","year":"2014","journal-title":"J Hematol Thromboembolic Dis"},{"issue":"1","key":"10.1002\/rth2.12457_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5045\/br.2015.50.1.19","article-title":"Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res"},{"issue":"3","key":"10.1002\/rth2.12457_bb0060","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia: discontinuation of eltrombopag in primary ITP","volume":"90","author":"Gonz\u00e1lez\u2010L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1002\/rth2.12457_bb0065","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4081\/hr.2015.5673","article-title":"Feasibility of romiplostim discontinuation in adult thrombopoietin\u2010receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice","volume":"7","author":"Carpenedo","year":"2015","journal-title":"Hematol Rep"},{"issue":"1","key":"10.1002\/rth2.12457_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-015-1793-1","article-title":"Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin\u2010receptor agonists in adults","volume":"102","author":"\u010cervinek","year":"2015","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1002\/rth2.12457_bb0075","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1002\/rth2.12457_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MBC.0000000000000380","article-title":"Efficacy and safety of eltrombopag in treatment\u2010refractory primary immune thrombocytopenia: a retrospective study","volume":"27","author":"Eser","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1002\/rth2.12457_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1002\/rth2.12457_bb0090","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.3324\/haematol.2016.151886","article-title":"Remissions after long\u2010term use of romiplostim for immune thrombocytopenia","volume":"101","author":"Marshall","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/rth2.12457_bb0095","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"issue":"14","key":"10.1002\/rth2.12457_bb0100","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1002\/rth2.12457_bb0105","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12457_bb0110","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.blre.2019.100647","article-title":"Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real\u2010world recommendations","volume":"41","author":"Zaja","year":"2020","journal-title":"Blood Rev"},{"key":"10.1002\/rth2.12457_bb0115","unstructured":"Cooper N, Bird R, Takaaki H, Kuter DJ, Lozano ML, Michel M, et al. Tapering and Discontinuation of Thrombopoietin Receptor Agonists in ITP: Consensus Summary of Expert Opinions. Poster presented at: 24th Congress of the European Hematology Association (EHA); 2019 Jun 13; Amsterdam, The Netherlands."},{"issue":"9","key":"10.1002\/rth2.12457_bb0120","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1002\/rth2.12457_bb0125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/qhc.11.4.358","article-title":"Research methods used in developing and applying quality indicators in primary care","volume":"11","author":"Campbell","year":"2002","journal-title":"Qual Saf Health Care"},{"key":"10.1002\/rth2.12457_bb0130","unstructured":"Fitch K, editor. The Rand\/UCLA appropriateness method user\u2019s manual. Santa Monica: Rand; 2001. 109 p."},{"issue":"4","key":"10.1002\/rth2.12457_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.12169","article-title":"Repeated short\u2010term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)","volume":"160","author":"Bussel","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1002\/rth2.12457_bb0140","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12185-013-1439-0","article-title":"Romiplostim as early treatment for refractory primary immune thrombocytopenia","volume":"98","author":"Contis","year":"2013","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1002\/rth2.12457_bb0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12185-013-1401-1","article-title":"Oral eltrombopag for up to three years is safe and well\u2010tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open\u2010label, extension study","volume":"98","author":"Katsutani","year":"2013","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1002\/rth2.12457_bb0150","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.003","article-title":"Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia","volume":"4","author":"Khalafallah","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"16","key":"10.1002\/rth2.12457_bb0155","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","article-title":"Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2\u2010year results of 72 adults in a romiplostim compassionate\u2010use program","volume":"118","author":"Khellaf","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12457_bb0160","first-page":"1","article-title":"Sustained remission in patients with primary immune thrombocytopenia after romiplostim tapering and discontinuation: a case series in real life management in Spain","volume":"2017","author":"Mingot\u2010Castellano","year":"2017","journal-title":"Case Rep Hematol"},{"issue":"3","key":"10.1002\/rth2.12457_bb0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12185-012-1154-2","article-title":"Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura","volume":"96","author":"Noronha","year":"2012","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1002\/rth2.12457_bb0170","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00277-012-1437-y","article-title":"Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia","volume":"91","author":"Perera","year":"2012","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1002\/rth2.12457_bb0175","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/ccr3.920","article-title":"Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case","volume":"5","author":"Santoro","year":"2017","journal-title":"Clin Case Rep"},{"key":"10.1002\/rth2.12457_bb0180","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ejh.12165","article-title":"Complete remission of refractory immune thrombocytopenia (ITP) with a short course of romiplostim","volume":"91","author":"Thachil","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1002\/rth2.12457_bb0185","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.4081\/hr.2011.e20","article-title":"Total remission of severe immune thrombocytopenia after short term treatment with romiplostim","volume":"3","author":"Vlachaki","year":"2011","journal-title":"Hematol Rep Former Hematol Rev"},{"issue":"2","key":"10.1002\/rth2.12457_bb0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MBC.0000000000000794","article-title":"Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review","volume":"30","author":"Wang","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"10.1002\/rth2.12457_bb0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1179\/1607845415Y.0000000041","article-title":"Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim","volume":"21","author":"Bussel","year":"2016","journal-title":"Hematology"},{"issue":"3","key":"10.1002\/rth2.12457_bb0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"Kuter","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1002\/rth2.12457_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. Wright JM, editor","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1002\/rth2.12457_bb0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.1995.03530080048040","article-title":"Validity of criteria used for detecting underuse of coronary revascularization","volume":"274","author":"Kravitz","year":"1995","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/rth2.12457_bb0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM200103013440906","article-title":"Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization","volume":"344","author":"Hemingway","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/rth2.12457_bb0220","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2011.12.001","volume":"59","author":"Patel","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1002\/rth2.12457_bb0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjcard.2015.03.057","article-title":"Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)","volume":"116","author":"Bradley","year":"2015","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1002\/rth2.12457_bb0230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/1744666X.2019.1587294","article-title":"Avatrombopag for the treatment of immune thrombocytopenia","volume":"15","author":"D\u0142ugosz\u2010Danecka","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1002\/rth2.12457_bb0235","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-200969030-00006","article-title":"Romiplostim","volume":"69","author":"Frampton","year":"2009","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/rth2.12457_bb0240","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00003495-200969050-00005","article-title":"Eltrombopag","volume":"69","author":"Garnock\u2010Jones","year":"2009","journal-title":"Drugs"},{"issue":"26","key":"10.1002\/rth2.12457_bb0245","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","article-title":"The reproducibility of a method to identify the overuse and underuse of medical procedures","volume":"338","author":"Shekelle","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/rth2.12457_bb0250","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/pbc.26003","article-title":"Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study: thrombopoietin receptor agonist use in children","volume":"63","author":"Neunert","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/rth2.12457_bb0255","unstructured":"Dana\u2010Farber\/Boston Children\u2019s Cancer and Blood Disorders Center. ITP Information for Kids [Internet]. [cited 2020 May 13]. Available from: http:\/\/www.danafarberbostonchildrens.org\/conditions\/blood\u2010disorders\/immune\u2010thrombocytopenic\u2010purpura\/itp\u2010kids.aspx"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12457","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:20:57Z","timestamp":1762863657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922013085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2475037922013085"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12457","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND\/UCLA modified Delphi panel method","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}